References
- Clark RE, Brammer CG. Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. Bone Marrow Transplant1998;22:859–863.
- Tournilhac O, Cazin B, Lepretre S, . Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood2004;103:363–365.
- Morgan S, Seymour JF, Grigg A, . Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine. Leukemia2004;18:1034.
- Popat U, Saliba R, Thandi R, . Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant2009;15:718–723.
- Nazha A, Cook R, Vogl DT, . Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen. Bone Marrow Transplant2011;46:59–63.
- Cavallo F, Bringhen S, Milone G, . Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia2011;25:1627–1631.
- Sugrue MW, Williams K, Pollock BH, . Characterization and outcome of “hard to mobilize” lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma2000;39: 509–519.
- DiPersio JF, Ho AD, Hanrahan J, . Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting. Biol Blood Marrow Transplant2011;17:943–955.
- Crocchiolo R, Chabannon C, El-Cheikh J, . Poor autologous mobilization status does not impact on hematological recovery but affects outcome after allogeneic stem cell transplant for lymphoma and myeloma. Leuk Lymphoma2012;53;XXX–XXX.
- Thoma MD, Huneke TJ, DeCook LJ, . Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant2012;18:600–607.
- Hiwase DK, Hiwase S, Bailey M, . Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant2008;14:116–124.
- Porrata LF, Inwards DJ, Ansell SM, . Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant2008;14:807–816.